These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 33415571)
1. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. Mamesaya N; Muramatsu K; Yabe M; Kodama H; Nishioka N; Miyawaki T; Miyawaki E; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Harada H; Sugino T; Shimizu T; Gon Y; Takahashi T Int J Clin Oncol; 2021 Apr; 26(4):659-669. PubMed ID: 33415571 [TBL] [Abstract][Full Text] [Related]
2. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021 [TBL] [Abstract][Full Text] [Related]
3. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. Shirasawa M; Yoshida T; Imabayashi T; Okuma K; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Tsuchida T; Yamamoto N; Nakayama Y; Watanabe SI; Motoi N; Ohe Y Eur J Cancer; 2022 Feb; 162():1-10. PubMed ID: 34936940 [TBL] [Abstract][Full Text] [Related]
4. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515 [TBL] [Abstract][Full Text] [Related]
5. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144 [TBL] [Abstract][Full Text] [Related]
6. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy]. Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339 [No Abstract] [Full Text] [Related]
7. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab. Bryant AK; Sankar K; Strohbehn GW; Zhao L; Daniel V; Elliott D; Ramnath N; Green MD Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):752-758. PubMed ID: 35450753 [TBL] [Abstract][Full Text] [Related]
8. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536 [TBL] [Abstract][Full Text] [Related]
9. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944 [TBL] [Abstract][Full Text] [Related]
10. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study. Castro NM; Moura F; Hada AL; Garcia D; Victor EDS; Schvartsman G; Carvalho L; Fernandes MLC; Martins RS; Silva EFD; Santos SSMBD; Taniwaki L; Taranto P; Pontes J; Beal JR; Dutra ACP; Oliveira Filho JB; Araujo SEA; Usón Junior PLS Einstein (Sao Paulo); 2024; 22():eAO0575. PubMed ID: 38922219 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Guberina M; Guberina N; Pöttgen C; Gauler T; Richlitzki C; Metzenmacher M; Wiesweg M; Plönes T; Forsting M; Wetter A; Herrmann K; Hautzel H; Darwiche K; Theegarten D; Aigner C; Schuler M; Stuschke M; Eberhardt WE Immunotherapy; 2022 Aug; 14(12):927-944. PubMed ID: 35822656 [TBL] [Abstract][Full Text] [Related]
13. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET. Pouw JEE; Hashemi SMS; Huisman MC; Wijngaarden JE; Slebe M; Oprea-Lager DE; Zwezerijnen GJC; Vugts D; Ulas EB; de Gruijl TD; Radonic T; Senan S; Menke-van der Houven van Oordt CW; Bahce I J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38302416 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study. Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075 [TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). Tufman A; Neumann J; Manapov F; Sellmer L; Jung A; Kauffmann-Guerrero D; Kahnert K; Mertsch P; Borgmeier A; Semrau S; Rittmeyer A; Ulm B; Ulm K; Flentje M; Fietkau R; Huber RM Lung Cancer; 2021 Oct; 160():17-27. PubMed ID: 34371299 [TBL] [Abstract][Full Text] [Related]
16. The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. Skov BG; Rørvig SB; Jensen THL; Skov T Mod Pathol; 2020 Jan; 33(1):109-117. PubMed ID: 31383957 [TBL] [Abstract][Full Text] [Related]